The administration of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs), as well as aldosterone receptor antagonists (mineralocorticoid receptor antagonists, MRAs), have substantially improved clinical outcomes in patients with DCM, however, these classic treatment are inadequate in counteracting an overactivated RAAS in patients with DCM due to their inherent limitations (Agarwal et al., 2021; Adamo et al., 2022). This evidence concerns the gene ACE and familial dilated cardiomyopathy.